Lantheus Holdings Inc (NASDAQ:LNTH) Director Sells $138,048.26 in Stock

Lantheus Holdings Inc (NASDAQ:LNTH) Director Brian A. Markison sold 4,918 shares of Lantheus stock in a transaction dated Wednesday, July 10th. The stock was sold at an average price of $28.07, for a total value of $138,048.26. Following the completion of the sale, the director now owns 27,549 shares of the company’s stock, valued at $773,300.43. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

LNTH stock traded up $0.10 during midday trading on Friday, reaching $27.76. The stock had a trading volume of 354,498 shares, compared to its average volume of 349,169. The business’s fifty day moving average price is $26.52. The company has a current ratio of 4.57, a quick ratio of 3.82 and a debt-to-equity ratio of 3.16. The company has a market capitalization of $1.07 billion, a price-to-earnings ratio of 29.53, a price-to-earnings-growth ratio of 2.11 and a beta of 1.49. Lantheus Holdings Inc has a twelve month low of $12.59 and a twelve month high of $29.80.

Lantheus (NASDAQ:LNTH) last announced its quarterly earnings data on Tuesday, April 30th. The medical equipment provider reported $0.28 EPS for the quarter, topping the Zacks’ consensus estimate of $0.25 by $0.03. The firm had revenue of $86.51 million during the quarter, compared to analyst estimates of $86.80 million. Lantheus had a return on equity of 59.57% and a net margin of 12.17%. Equities analysts anticipate that Lantheus Holdings Inc will post 1.11 EPS for the current year.

A number of analysts recently commented on LNTH shares. BidaskClub lowered Xencor from a “sell” rating to a “strong sell” rating in a research report on Tuesday, June 11th. Zacks Investment Research lowered GenMark Diagnostics from a “hold” rating to a “sell” rating in a research report on Wednesday, April 24th. Two investment analysts have rated the stock with a hold rating and three have issued a buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus price target of $23.33.

A number of hedge funds have recently made changes to their positions in the stock. LSV Asset Management increased its position in Lantheus by 2.1% in the first quarter. LSV Asset Management now owns 1,633,414 shares of the medical equipment provider’s stock worth $39,985,000 after purchasing an additional 33,882 shares during the period. Vaughan Nelson Investment Management L.P. grew its position in shares of Lantheus by 5.6% during the 1st quarter. Vaughan Nelson Investment Management L.P. now owns 1,587,904 shares of the medical equipment provider’s stock worth $38,872,000 after buying an additional 84,529 shares during the period. Dimensional Fund Advisors LP grew its position in shares of Lantheus by 5.0% during the 4th quarter. Dimensional Fund Advisors LP now owns 1,379,017 shares of the medical equipment provider’s stock worth $21,581,000 after buying an additional 65,609 shares during the period. JPMorgan Chase & Co. grew its position in shares of Lantheus by 30.5% during the 1st quarter. JPMorgan Chase & Co. now owns 729,960 shares of the medical equipment provider’s stock worth $17,870,000 after buying an additional 170,524 shares during the period. Finally, Raging Capital Management LLC grew its position in shares of Lantheus by 43.9% during the 4th quarter. Raging Capital Management LLC now owns 553,993 shares of the medical equipment provider’s stock worth $8,670,000 after buying an additional 168,993 shares during the period. Hedge funds and other institutional investors own 92.55% of the company’s stock.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic medical imaging agents and products that assist clinicians in the diagnosis and treatment of cardiovascular and other diseases worldwide. Its principal products include DEFINITY, a microbubble contrast agent used in ultrasound exams of the heart; and TechneLite, a technetium generator that provides the nuclear material used in nuclear medicine procedures.

Further Reading: Forex

Insider Buying and Selling by Quarter for Lantheus (NASDAQ:LNTH)

Receive News & Ratings for Lantheus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lantheus and related companies with MarketBeat.com's FREE daily email newsletter.